Archive | February, 2016

Researchers identify biomarker for early cognitive decline in Parkinson’s disease patients using PPMI data

Many patients with Parkinson?s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson?s Disease indicates that lower concentrations of ?-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.

Continue reading...

Dr. Omar El-Agnaf to use PPMI biospecimens for validation of cerebral spinal fluid ?-synuclein species as surrogate biomarkers for Parkinson?s disease

We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF ?-synuclein species as surrogate biomarkers for Parkinson?s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]

Continue reading...

Dr. Martin Rabey to use PPMI biospecimens for validation of a blood based gene expression assay

A critical component of PPMI is the standardized, longitudinal collection of biospecimens. Each month the Biospecimen Review Committee examines requests for biospecimens collected through the PPMI study. We are excited to announce approval for Dr. Martin Rabey, the Chief Medical Officer of BioShai Ltd, for a project entitled: Validation of a blood based gene expression […]

Continue reading...